3Henschke CI,Yip R, Miettinen OS,et al. Women susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer[J]. JAMA,2006,96(2) :180 - 184.
6Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas[J]. Cancer Res,2005,65(5) :1642 - 1646.
8Fu JB, Kau TY, Severson RK, et al. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest, 2005, 127:768-777.
9Pauk N, Kubik A, Zatloukal P, et al. Lung cancer in women. Lung Cancer, 2005, 48:1-9.
10Patel JD. Lung cancer in women. J Clin Oncol, 2005, 23:3212- 3218.
7NCCN. The NCCN Non-small cell lung cancer clinical practice guide-lines in oncology (version 2. 2012)EEB/OL]. Fort Washington~ NC- CN,2011[2011-10-04-]. http:www, nccn. org/professionals/physician _gls/f_guidelines. asp # nscl.
8Gajra A, Newman N, Gamble GP, et al. Effect of number of lymph nodes sampled on outcome in patients with stage I non- small cell lung cancer[J]. J Clin Oncol, 2003,21 (6) : 1029-1034.
9Doddoli C, Aragon A, Barlesi F, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non- small cell lung cancer? [J]. Eur J Cardiothorac Surg, 2005,27 (4) :680-685.
10Wu YC, Lin CF, Hsu WH, et al. Long-term results of pathologi- cal stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control[J]. Eur J Cardiothorac Surg, 2003,24(6) : 994-1001.
